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1. Introduction 
Ovarian cancer is a commonly diagnosed and particularly deadly gynecologic malignancy 
worldwide. It ranks among the top ten diagnosed cancers and top five deadliest cancers in 
most countries (Ferlay et al., 2010). Several cancer incidence data sources have been used to 
measure ovarian cancer burden across the world; however, the statistics presented are often 
not population-based, which can lead to misrepresentation of the burden due to incomplete 
or inaccurate data. An accurate assessment of ovarian cancer burden is essential as incidence 
data are used for many purposes including to generate hypotheses regarding etiology, 
allocate resources and funding toward  new treatment discovery and clinical trials, and 
determine which populations of women may benefit from more education or greater 
surveillance for the disease.  The purpose of this chapter is to present global comprehensive 
ovarian cancer incidence data. Data collected are from several resources, and every effort is 
made to present only high-quality data from population-based data sources. Because of 
changing age structures of populations and differences in data quality and coverage of 
various data sources over time, only the most recent data are presented. This will aid in 
preventing misinterpretation of temporal trends. 
2. Data sources and interpretation 
Data on the incidence of ovarian cancer (the number of new cases per year) is collected by 
population-based cancer registries; however, only certain countries have national registries 
that collect this information. In the United States, a law passed in 1992 established nationwide 
cancer surveillance. This law resulted in the establishment of the National Program of Cancer 
Registries (NPCR), which is administered by the Centers for Disease Control and Prevention 
(CDC), and provides cancer incidence data for 96% of the U.S. population (U.S.Cancer 
Statistics Working Group, 2010). When combined with data  from the existing Surveillance, 
Epidemiology, and End Results (SEER) program, administered by the National Cancer 
Institute (NCI), 100% of the U.S. population is accounted for. Several other countries including 
Canada, Singapore, Denmark, Finland, Iceland, Norway, and Sweden have nationwide 
registry systems (Thun et al., 2011). Many other countries base their incidence on cancers 
collected in certain regions or groups of regions, and therefore these results vary in quality 
(Thun et al., 2011).  Cancer registries typically require a period of one to two years to collect all 
required information on cancer diagnoses in the geographic areas covered. For that reason, 
most incidence data reported is two to three years behind the current calendar year.  
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Incidence rates take into account the number of new cases of cancer (numerator), and also 
the population at risk for the cancer (denominator). Most incidence rates are age-adjusted or 
standardized in order to allow comparisons across populations with differing age 
structures. Several age distributions are available for standardization. In international data, 
which is compiled from population-based registries by the International Agency for 
Research on Cancer (IARC), the 1960 world standard population is used (Ferlay et al., 2010). 
Within specific countries, such as the United States, the 2000 U.S. standard population is 
used (Thun et al., 2011; U.S.Cancer Statistics Working Group, 2010). Differences in age 
standardization methodology can result in a variance of rates reported from the same 
country. Age-specific rates for certain age poulations (e.g., children) are often reported; 
these rates are often not age-adjusted or standardized. Most rates are expressed per 100,000 
persons, and in the case of ovarian cancer per 100,000 women. 
In this chapter, data are presented from a variety of sources, including monographs and 
peer-reviewed literature. Data are presented from the IARC public-use monograph 
(GLOBOCAN 2008) on case counts and rates for countries around the world (Ferlay et al., 
2010). Since the United States also produces a comprehensive monograph annually, data are 
also presented for this country from the public-use United States Cancer Statistics (USCS) 
website (U.S.Cancer Statistics Working Group, 2010).  Overall case and rate data from peer-
reviewed articles are also included for countries (including the United States) that have 
published ovarian cancer incidence information from population-based registries. These 
articles may be a better source of data for some countries than monographs, as they may 
contain more complete or up-to-date information. Demographic- and clinical factor-specific 
data, and temporal trends are presented from monographs when available, and are 
supplemented with data from the most recent peer-reviewed publications for all countries 
available. Clinical factor data  and temporal trends especially (histology, stage, laterality) are 
most often contained in peer-reviewed publications as opposed to monogaphs.  To prevent 
misinterpretation, only data from the most recent publications (monograph or peer-
reviewed publication) are presented. Table 1 lists data sources, years and population 
covered for each.   
3. Global ovarian cancer incidence 
A total of 224,747 new cases of ovarian cancer were reported worldwide in 2008, with 99,521 
cases being diagnosed in more developed regions, and 125,226 being diagnosed in less 
developed regions (Ferlay et al., 2010). Ovarian cancer was the seventh most common cancer 
diagnosis among women in the world overall, and fifth most common cancer diagnosis 
among women in more developed regions (Ferlay et al., 2010). The world rate is estimated 
to be 6.3 per 100,000, and is higher in developed countries and regions (9.3) compared to 
others (Ferlay et al., 2010).  Incidence rates for selected regions, continents and countries are 
shown in Table 2. Rates range from 3.8 in the Southern and Western African regions  to 11.8 
in the region of Northern Europe. Continental rates are highest in Europe (10.1), followed by 
North America (8.7), Australia (including New Zealand, 7.8), South America (6.2), Asia (5.1), 
and Africa (4.2). 
Figure 1 displays a categorization of ovarian cancer incidence rates around the world. Rates 
for individual countries range from 1.8 in Samoa to 14.6 in Latvia (Ferlay et al., 2010). 
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Author and publication year Data year(s) Population* 
Ferlay et al., 2010 2008 World 
U.S. Cancer Statistics 
Working Group, 2010 
2007 United States (99.1%) 
Koper et al., 1996 1989-1991 Netherlands  
Ioka et al., 2003 1975-1998 Osaka, Japan 
Mahdy et al., 1999 1988-1997 Alexandria, Egypt 
Zambon et al., 2004 1986-1997 Several regions in Italy 
Kohler et al., 2011 Rates: 2003-2007;  
Trends: 1998-2007 
United States (93%) 
Tamakoshi et al., 2001 1975-1993 Several regions in Japan 
Jin et al.,1993 1979-1989 Shanghai, China 
Dey et al., 2010 1999-2002 Tanta, Egypt 
Minelli et al., 2007 1998-2002 Umbria, Italy 
Goodman & Howe, 2003 1992-1997 United States (52%) 
Goodman et al., 2003 1992-1997 United States (52%) 
Boger-Megiddo & Weiss, 
2005 
1992-2000 United States (26%) 
Stiller, 2007 NR World 
Brookfield et al., 2009 1973-2005 United States (9%) 
Poynter et al., 2010  1975-2006 United States (9%) 
Smith et al., 2006 1973-2002 United States (9%) 
Goodman and Shvetsov, 
2009 
1995-2004 United States (64%) 
Jaaback et al., 2006 1993-2003 Royal United Hospital, UK 
Stewart et al, 2007 1998-2003 United States (83.1%) 
Riska et al., 2003 1953-1997 Finland 
Pfeiffer et al., 1989 1978-1983 Denmark 
 
Table 1. Data years and populations covered for monographs and articles cited throughout 
this chapter. *The population coverage for a particular country or region is provided when 
available from reports. NR=not reported. 
In the United States, 20,749 ovarian cases were diagnosed in 2007 (the most recent year for 
which data are available), for an incidence rate of 12.2 per 100,000 women (U.S.Cancer 
Statistics Working Group, 2010). Koper et al. reported a rate of 14.9 in the Netherlands, 
similar to that found in the United States (Koper et al., 1996). In Osaka, Japan the overall rate 
reported was 5.4 (Ioka et al., 2003), and in Alexandria, Egypt, the rate was 3.16 (Mahdy et al., 
1999). An Italian network of cancer registries reported 7,690 cases of ovarian cancer from 
1986 through 1997 (Zambon et al., 2004).  Few countries publish trends in ovarian cancer 
incidence over time. This may be due to differing methods of data collection and data 
quality issues, especially for countries that do not have a national registry. In the United 
States, a recent report estimates that ovarian cancer incidence has been decreasing since 
1998, with a significant decline of 2.3% per year from 2003-2007 (Kohler et al., 2011). The 
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reasons for this decrease are unclear, but are likely not artefactual due to the long-standing 
high-quality data available for the United States. A Japanese analysis based on data from 
several regional cancer registries reported a 1.5 fold increase in ovarian cancer rates from 
1975 to 1993 (Tamakoshi et al., 2001).  The Chinese Shanghai Cancer Registry also reported 
an increase in ovarian cancer incidence from 1979-1989 (Jin et al., 1993). Some of these 
increases may be due to increases in population coverage or completeness of data within the 
registry; however, the Chinese increase is thought to be a birth cohort effect in women born 
between 1925-1935 (Jin et al., 1993). 
 
 
Region  Case count Rate 
World 224747   6.3   
More developed regions 99521   9.3   
Less developed regions 125226   5.0   
Africa 13976   4.2   
Sub-Saharan Africa 9961   4.0   
Eastern Africa 3840   4.0   
Middle Africa 1728   4.3   
Northern Africa 4015   4.8   
Southern Africa 893   3.8   
Western Africa 3500   3.8   
Latin America and Caribbean 16981   5.9   
Caribbean 1005   4.3   
Central America 3571   5.2   
South America 12405   6.2   
Northern America 23895   8.7   
Asia 102408   5.1   
Eastern Asia 40831   4.3   
South-Eastern Asia 18580   6.6   
South-Central Asia 38797   5.5   
Western Asia 4200   4.8   
Europe 65697   10.1   
Central and Eastern Europe 27071   11.0   
Northern Europe 10256   11.8   
Southern Europe 11751   8.4   
Western Europe 16619   8.9   
Oceania 1790   7.6   
Australia/New Zealand 1601   7.8   
Melanesia 161   5.1   
Micronesia/Polynesia 28   5.5   
Micronesia 15   6.1   
Polynesia 13   5.0   
Table 2. Ovarian cancer incidence counts and rates for selected regions and continents 
worldwide. Rates are per 100,000 women and age-standardized to the 1960 world standard 
population. Source: Ferlay et al., 2011. 
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Fig. 1. Map of ovarian cancer rates worldwide. Rates are per 100,000 women and are age-
standardized to the 1960 world standard population. Data were not included for white areas 
on the map. Source: Ferlay et al., 2011. 
Incidence patterns stratified by region can assist with assessment of environmental or 
cultural factors that may increase risk. Regional variation in ovarian cancer rates exists, and 
this variation can sometimes be substantial. Percentages of ovarian cancer cases in World 
Health Organization regions are shown in Figure 2, these percentages range from 4.4% in 
the Eastern Mediterranean region (EMRO) to 31.0% in the European region (EURO) (Ferlay 
et al., 2010).   
 
 
Fig. 2. Percentage of ovarian cancer cases by World Health Organization (WHO) health 
organization region. SEARO=Southeast Asia Regional Office, EURO=European Regional 
Office; EMRO=Eastern Mediterranean Regional Office; WPRO=Western Pacific Regional 
Office; AFRO=Africa Regional Office; PAHO=Pan American Health Organization. Source: 
Ferlay et al., 2011. 
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These numbers do not take into account the population, and may likely be reflective of the 
population coverage of cancer registration in these areas. In the United States, ovarian 
cancer incidence rates are similar among the Northeast, Midwest, and South U.S. Census 
regions (11.7-12.9), and individual state rates range from 7.3 to 15.4 (U.S.Cancer Statistics 
Working Group, 2010).   Studies in Egypt (Dey et al., 2010) and Italy (Minelli et al., 2007) 
have found ovarian cancer rates to be higher in urban compared to rural areas.  Table 3 
displays the ovarian cancer case counts and incidence rates by U.S. census region and 
division, and by state in the United States. 
 
 
 
Geographic Area Case count Rate 
United States 20,749 12.2 
Northeast 4,375 12.9 
New England 1,057 11.9 
Connecticut 268 12.1 
Maine 98 11.8 
Massachusetts 473 11.8 
New Hampshire 99 12.5 
Rhode Island 77 11.8 
Vermont 42 10.8 
Middle Atlantic 3,318 13.3 
New Jersey 696 13.3 
New York 1,516 13 
Pennsylvania 1,106 13.7 
Midwest 4,724 12.3 
East North Central 3,318 12.4 
Illinois 896 12.6 
Indiana 428 11.7 
Michigan 755 13.1 
Detroit 320 13.7 
Ohio 827 12 
Wisconsin 412 12.7 
West North Central 1,406 12.1 
Iowa 248 13.7 
Kansas 196 12.6 
Minnesota 352 12.1 
Missouri 403 11.5 
Nebraska 108 10.4 
North Dakota 46 12.9 
South Dakota 53 11.4 
South 7,298 11.7 
South Atlantic 4,045 11.9 
Delaware 78 15.4 
District of Columbia 31 9.4 
Florida 1,391 11.8 
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Geographic Area Case count Rate 
Georgia 638 13.2 
Atlanta 191 12.1 
Maryland 367 11.2 
North Carolina 612 12 
South Carolina 295 11.4 
Virginia 491 11.3 
West Virginia 142 11.9 
East South Central 1,187 11.2 
Alabama 312 11.1 
Kentucky 278 11.3 
Mississippi 173 10.3 
Tennessee 424 11.8 
West South Central 2,066 11.6 
Arkansas 188 11 
Louisiana* 237 9.6 
Oklahoma 272 13 
Texas 1,369 11.8 
West  NR NR  
Mountain  NR NR  
Arizona 397 11.6 
Colorado 334 13.3 
Idaho 119 15 
Montana 65 11 
Nevada  NR NR  
New Mexico 129 11.9 
Utah 103 9.1 
Wyoming 22 7.3 
Pacific 3,183 12.4 
Alaska 37 13.1 
California 2,319 12.3 
San Francisco-Oakland 317 12.8 
San Jose-Monterey 158 12.8 
Los Angeles 626 12.6 
Hawaii 92 12.2 
Oregon 280 12.7 
Washington 455 12.5 
Seattle-Puget Sound 332 13.2 
 
Table 3. Ovarian cancer incidence counts and rates for the United States, U.S. Census regions 
and divisions and individual states. Rates are per 100,000 women and age-adjusted to the 
2000 U.S. standard. Data presented cover 99.1% of the U.S. population. *Indicates that data 
differ from that presented by the Louisiana Tumor Registry and the SEER Program. NR=not 
reported.  Source: (U.S.Cancer Statistics Working Group, 2010). 
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3.1 Clinical factors (histology, stage, laterality) and ovarian cancer incidence 
Ovarian cancers are classified into three main histologic groups: epithelial tumors, sex 
cord-stromal tumors, and germ cell tumors (Cannistra et al., 2011). Epithelial tumors are 
believed to originate from the surface epithelium of the ovary (Chen et al., 2003). There 
are four main subtypes of epithelial tumors: serous, mucinous, endometrioid, and clear 
cell adenocarcinomas (Chen et al., 2003). Sex cord-stromal tumors originate in granulosa 
or thecal cells, or other stromal cells. Germ cell tumors are formed by cells that are 
believed to be derived from primordial germ cells, and they include the subtypes 
dysgerminomas, teratomas, and yolk sac tumors, among other subtypes (Chen et al., 
2003). Several histologic-specific ovarian cancer incidence studies are published in the 
peer-reviewed literature, and most are based on populations in the United States. In a 
2003 publication, Goodman et al. reported that 91.9% of ovarian tumors were epithelial, 
1.2% were sex cord-stromal, and 1.9% were germ cell (Goodman & Howe, 2003). Serous 
adenocarcinoma was the most incident epithelial subtype, accounting for 37.7% of all 
ovarian tumors (Goodman & Howe, 2003). These U.S. data are consistent with those from 
the Netherlands, where 89% of all ovarian cancer diagnoses were reported to be epithelial 
tumors (Koper et al., 1996).   
Effective early detection methods for ovarian cancer do not currently exist, and symptoms 
for ovarian cancer can be vague and gastrointestinal (as opposed to gynecologic) in nature. 
Because of this, many ovarian tumors are diagnosed at advanced stages. In the United 
States, studies show that about 20% of all ovarian cancer cases are localized stage at 
diagnosis, about 13% are regional stage, and the majority are distant stage (58%) (Goodman 
et al., 2003). This distribution differs by histologic type. Sex cord-stromal and germ cell 
tumors are more often diagnosed at localized stages (>50%) compared to epithelial tumors 
(19%) (Goodman et al., 2003). In the Netherlands, two thirds of all ovarian cancers were 
found to be extended to the pelvis or beyond at diagnosis (Koper et al., 1996).    
There is a paucity of analyses on laterality.  In a U.S. population, serous adenocarcinomas 
were were found to be bilateral at diagnoses in 57.5% of cases, and other epithelial tumors 
ranged in bilaterality from 13.3% to 35.6%  (Boger-Megiddo & Weiss, 2005).  
3.2 Demographic factors (age and race/ethnicity) and ovarian cancer incidence 
Age is commonly reported in most ovarian cancer incidence publications. Globally, 
ovarian cancer incidence rates increase with advancing age and range from 0.2 among 
those aged 0-14 to 29.2 among those aged 75 years and older (Ferlay et al., 2010). A similar 
pattern is seen in more developed countries;  however, the incidence rates are higher and 
range from 0.3 to 42.6 (Ferlay et al., 2010). In the United States, ovarian cancer incidence 
rates range from 0.3 in those aged 5-9 years to 44.2 in women aged 85 and older 
(U.S.Cancer Statistics Working Group, 2010). The peak ovarian cancer incidence rate of 
50.6 is found among women aged 80-84 in the United States (U.S.Cancer Statistics 
Working Group, 2010). In developing countries, ovarian cancer occurs in younger women. 
In Ghana, the mean age of ovarian cases seen in a teaching hospital was 46.4 years 
(Nkyekyer, 2000), and in Kyrgyzstan, the average age of ovarian cancer patients was 37.9, 
with the highest incidence rate (11.2 per 60,0000 women) observed among those aged 40-
49 (Igisinov & Umaralieva, 2008).    
Several published studies limit their age-specific ovarian cancer analyses to children and 
adolescents, and many of these specifically report on ovarian germ cell tumors, which are 
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diagnosed in high numbers among children and adolescents (Young et al., 2003). In an 
international study of cancer among adolescents, ovarian germ cell tumors were found in 
the highest rates among those aged 15-19 (Stiller, 2007). A study from the United States 
reported an overall ovarian cancer incidence rate of 0.102 for girls aged 9 years and younger, 
and 1.072 for girls aged 10-19 years (Brookfield et al., 2009). Other studies in the United 
States comparing germ cell tumor rates concluded that the incidence of ovarian germ cell 
tumors was significantly higher in Hispanic compared to non-Hispanic girls aged 10-19 
(Poynter et al., 2010; Smith et al., 2006), and Asian/Pacific Islanders (0.059) compared to 
other ethnicities (Smith et al., 2006). Consistent with international studies, girls aged 15-19 
years had the highest germ cell rates in the United States and it was reported that these rates 
are increasing (Smith et al., 2006).  
Most reports examining ovarian cancer by race and/or ethnicity are in the United States 
population. This is likely due to the diversity in the racial and ethnic make-up of the 
United States. In 2007,  it was reported that ovarian cancer incidence rates were highest 
among U.S. white women (12.6), followed by black (9.1), Asian/Pacific Islander (A/PI) 
(9.0), and  American Indian/Alaska Native (AI/AN) women (8.0) (U.S.Cancer Statistics 
Working Group, 2010). Rates were lower in Hispanic women (10.2) compared to non-
Hispanic women (11.3) (U.S.Cancer Statistics Working Group, 2010). Some U.S. studies 
have used enhanced population denominator data to probe race-specific rates further in 
an attempt to provide more accurate or meaningful rates. Studies using denominator data 
adjusted for Indian Health Service delivery regions in the United States  (Espey et al., 
2007; Kohler et al., 2011) report ovarian cancer incidence rates of 11.3 (Kohler et al., 2011) 
among AI/AN women. The most recent report examining trends concluded that ovarian 
cancer incidence rates have been decreasing at about 1.0% per year since 1998 among most 
racial and ethnic groups in the United States, with the exception of A/PI women (Kohler 
et al., 2011).    
4. Primary peritoneal and primary fallopian tube cancers 
Primary peritoneal cancer (PPC) and primary fallopian tube cancer (PFTC) are rare 
malignancies, but share many similarities to ovarian cancer. These three cancers are 
clinically managed in a similar manner (Cannistra et al., 2011). Due to their rarity, these 
cancers are generally not reported as a distinct or separate category in statistical 
monographs; reports of their incidence are limited to relatively few peer-reviewed 
publications. In the United States, the incidence rate of PPC is estimated to be 0.678 
(Goodman & Shvetsov, 2009a). PPCs were diagnosed at later ages (mean age 67 years) and 
more  advanced stages (85% regional/distant diagnoses) than ovarian cancer (mean age 
63, 75% regional/distant diagnoses) in this same population (Goodman & Shvetsov, 
2009a). In contrast, a study from a UK cancer center examining PPC found that age and 
tumor characteristics (stage and grade) were similar among ovarian and primary 
peritoneal tumors (Jaaback et al., 2006). The U.S. incidence rate of PFTC is 0.41 (Stewart et 
al., 2007). The vast majority of PFTCs (89%) are unilateral at diagnosis, and about 30% are 
diagnosed at each localized, regional and distant stages (Stewart et al., 2007). U.S. PFTC 
rates are  similar to those reported from Finland (0.3) (Riska et al., 2003) and Denmark 
(0.5)  (Pfeiffer et al., 1989). U.S. studies have suggested that the rates of both PPC 
(Goodman & Shvetsov, 2009a; Howe et al., 2001) and PFTC  (Goodman & Shvetsov, 2009a; 
Stewart et al., 2007) are increasing. It is thought that some of this increase may be due to 
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reduction in the misclassification of PPC and PFTC as ovarian cancer (Stewart et al., 2007, 
Goodman & Shvetsov, 2009b). 
5. Discussion 
Ovarian cancer incidence rates reported from countries with nationwide cancer registration 
and those from more developed countries are generally similar to each other.  In less 
developed countries and regions, ovarian cancer rates are relatively lower, and this is likely 
due in part to the lack of quality data from large portions of the population in these 
countries. Additionally, cancers that are related to infectious agents (i.e. not ovarian cancer), 
are some of the most incident cancers in developing countries (Thun et al., 2011). It should 
be noted; however, that while cancer overall has typically been more incident in 
industrialized and comparatively wealthy nations, it is suggested that cancer incidence is 
increasing in low and medium resource countries (Thun et al., 2009). This increase may be a 
result of an increased lifespan due to advances in medical treatment in these countries, as 
well as the adoption of Western patterns of diet, physical activity, and tobacco use (Thun et 
al., 2011).  
Several factors, including  genetic, reproductive, hormonal and behavioral factors have been 
suggested to increase risk for ovarian cancer.  Genetic factors perhaps have the strongest 
and most consistent association with increased risk for ovarian cancer. At least 10% of all 
epithelial ovarian cancers are reported to be hereditary, with the majority (about 90%) of 
these related to mutations in BRCA genes and 10% related to mutations associated with 
Lynch syndrome (Prat et al., 2005).  Hereditary ovarian cancers have distinct patterns from 
sporadic ovarian cancers. Many are diagnosed at younger ages and less advanced stages 
than sporadic ovarian cancers (Prat et al., 2005). Regarding reproductive factors, studies 
over several years have consistently associated nulliparity with increased risk of ovarian 
cancer (Modan et al., 2001; Risch et al, 1994; Vachon et al., 2002). It is estimated that 
nulliparity may increase risk only slighty in the average-risk population (relative risk 
[RR]=1.4, 95% confidence interval [CI] 1.9-2.4), but may have a more substantial effect in 
women with a family history of ovarian cancer (Vachon et al., 2002).  Hysterectomy and 
tubal ligation have been consistently associated with conferring a decreased risk for ovarian 
cancer.   Tubal ligation has been estimated to decrease risk substantially  (RR= 0.33, 95% CI 
0.16 to 0.64), while hysterectomy may have a weaker, but still protective association (RR= 
0.67, 95% CI 0.45 to 1.00) (Hankinson et al., 1993). Oral contraceptive use has been suggested 
to decrease risk for ovarian cancer, while post-menopausal hormone replacement therapy 
use is suggested to increase risk for ovarian cancer.  However, conclusions from hormonal 
studies have generally been less consistent and more difficult to interpret than genetic and 
reproductive factor studies.  Although some studies have shown a protective effect of oral 
contraceptives on ovarian cancer (Beral et al., 2008), IARC classifies estrogen, combined 
estrogen-progesterone oral contraceptives, and combined estrogen-progesterone hormone 
replacement therapy as class one carcinogens, concluding there is sufficient evidence for 
their carcinogenicity in humans (IARC 2007).  The relationship between behavioral factors, 
such as tobacco use, physical activity, and obesity and ovarian cancer has been less reported 
compared to the other factors mentioned. Available results are generally inconclusive. Some 
studies have suggested a modest increased risk of ovarian cancer in obese women 
(Leitzmann, et al., 2009); however, others have found no relationship between body mass 
index and ovarian cancer (Fairfield et al., 2002). Similarly with physical activity, one study 
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concluded there was a modest inverse association of physical activity and ovarian cancer 
risk (Biesma et al., 2006), while another concluded there was no association (Hannan et al., 
2004). Smoking has been shown to increase risk for the epithelial subtype mucinous 
adenocarcinoma, but does not increase risk for other more incident subtypes (Jordan et al., 
2006).  
6. Conclusion 
Although ovarian cancer patterns vary widely around the world, incidence rates are high in 
several regions. The etiology and natural history of ovarian cancer are poorly understood, 
and much more research is needed to elucidate factors that may increase or decrease risk for 
ovarian cancer. The analysis of incidence patterns both within and between populations is 
essential to revealing potential causes of and risk factors for ovarian cancer. Incidence rates 
from countries with high-quality data should continue to be analyzed with respect to 
histology and stage variation, as these types of analyses may provide clues to the 
pathogenesis of the disease.  Currently, a major goal of ovarian cancer research is to develop 
an effective test that can detect the disease at its earliest stages, which would ultimately 
result in decreased mortality. Increased knowledge of ovarian cancer etiology and 
pathogenesis would greatly enhance the development of this tool. Expansions in ovarian 
cancer incidence registration and analyses will be very valuable in this endeavor.  
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